Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Japanese Encephalitis Vaccine Available for Military

by Global Biodefense Staff
August 25, 2014
Japanese Encephalitis Vaccine Available for Military

Mosquitoes all over the globe carry and spread some of the most debilitating diseases known to man, and do so in a manner that’s often difficult to predict with any kind of certainty.

These vector-borne diseases can cause serious illness or can be fatal. Some of these diseases, such as Japanese encephalitis, referred to as JE, have the potential to cause extensive brain damage, which may result in seizures, paralysis, weakness, neurological or psychiatric problems. JE has no specific treatment if contracted.

“Our DOD beneficiaries tend to be an active population. Our children play outside and many of our adults spend a lot of time outdoors exploring the countryside in areas where the risk for JE is high,” said Col. Margaret Yacovone, director of the Military Vaccine Agency-Vaccine Healthcare Centers Network, or MILVAX-VHCN. “So, it is important to take measures to adequately protect against the disease threat.”

360,000 Americans Stationed in Endemic Areas

Protection from these illnesses starts with personal protective measures, such as insect repellant or limiting outdoor activities at dusk and dawn. However, the best method of protection – a vaccine — is available for JE, and is the most effective preventive measure for the near 360,000 U.S. military and civilian personnel, and their families, working and living in endemic countries in Asia.

The JE vaccine is recommended by the Centers for Disease Control and Prevention for people who stay longer than 30 days in endemic areas of Asia and the western Pacific during mosquito season. It should also be considered for short-term travelers to endemic areas during the JE virus transmission season. The vaccine is licensed by the Food and Drug Administration for use in people aged two months and older.

“We are concerned that some of our beneficiaries are unaware of the threat of JE. While the risk of infection from routine travel may be low, people who relocate to endemic areas are at the same risk as the local residents,” Yacovone said. “All beneficiaries transferring to these areas should be adequately vaccinated against JE according to CDC recommendations.”

A Routine Childhood Vaccine in Some Asian Countries

Navy Capt. Christopher Armstrong, deputy director of Clinical Services for MILVAX-VHCN, stressed that JE, while not seen in the U.S., is already clearly documented as a public health concern and is a routine childhood vaccination in several major Asian countries.

Japanese encephalitis is usually transmitted from June through October. While the risk of developing serious symptoms is low, the fatality rate once symptoms present is 20 to 30 percent. Another 30 to 50 percent of people who survive the disease can develop neurological and psychological problems, which “are unpredictable and cannot be repaired,” Yacovone said.

Up to 50 people per 100,000 who are infected with JE will develop clinical disease, according to the CDC. “The disease, if it develops, will result in crippling disability, if not death,” Armstrong said. “Getting vaccinated is a small price to pay to avoid that.”

Source: Military Vaccine Agency Vaccine Healthcare Centers Network, adapted.

Tags: Vaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC